CSPC Pharmaceutical Group (FRA:CVGU) Debt-to-EBITDA : (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:CVGU CSPC Pharmaceutical Group Ltd FRA:CVGU
85 GF Score
Price €3.68
GF Value €2.78
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is CSPC Pharmaceutical Group Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

CSPC Pharmaceutical Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was €34 Mil. CSPC Pharmaceutical Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was €50 Mil. CSPC Pharmaceutical Group's annualized EBITDA for the quarter that ended in Jun. 2026 was €2,050 Mil. CSPC Pharmaceutical Group's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 was 0.04.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for CSPC Pharmaceutical Group's Debt-to-EBITDA or its related term are showing as below:

FRA:CVGU' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.01   Med: 0.07   Max: 0.35
Current: 0.06

During the past 13 years, the highest Debt-to-EBITDA Ratio of CSPC Pharmaceutical Group was 0.35. The lowest was 0.01. And the median was 0.07.

FRA:CVGU's Debt-to-EBITDA is ranked better than
90.4% of 677 companies
in the Drug Manufacturers industry
Industry Median: 1.64 vs FRA:CVGU: 0.06

CSPC Pharmaceutical Group  (FRA:CVGU) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

CSPC Pharmaceutical Group Debt-to-EBITDA Related Terms

CSPC Pharmaceutical Group Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for CSPC Pharmaceutical Group's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CSPC Pharmaceutical Group Debt-to-EBITDA Chart

CSPC Pharmaceutical Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CSPC Pharmaceutical Group Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

FRA:CVGU vs LLY, JNJ, ABBV: Debt-to-EBITDA Comparison

For the Drug Manufacturers - General subindustry, CSPC Pharmaceutical Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CSPC Pharmaceutical Group Debt-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CSPC Pharmaceutical Group's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where CSPC Pharmaceutical Group's Debt-to-EBITDA falls into.


FRA:CVGU
85GF Score
CSPC Pharmaceutical Group Ltd FRA:CVGU
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CSPC Pharmaceutical Group Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

CSPC Pharmaceutical Group's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(56.098746536274 + 22.016287027121) / 777.61804068933
=0.10

CSPC Pharmaceutical Group's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(33.965898806769 + 50.142364519952) / 2050.1302583738
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2026) EBITDA data.

Is CSPC Pharmaceutical Group (FRA:CVGU) Overvalued in 2026?

Based on GuruFocus' analysis, CSPC Pharmaceutical Group stock appears to be overvalued. The current stock price of €3.68 is trading 32.4% above its estimated GF Value™ of €2.78. GuruFocus considers CSPC Pharmaceutical Group to be Significantly Overvalued.

Key valuation signals for FRA:CVGU:

  • Debt-to-EBITDA:
  • GF Value™: €2.78 vs. price of €3.68 (32.4% above fair value)
  • GF Score™: 85/100 with 3 warning signs

No single metric tells the full story. See the FRA:CVGU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CSPC Pharmaceutical Group Business Description

Address No.896 Zhongshandong Street, Gaoxin District, Hebei Province, Shijiazhuang, CHN, 050035
CSPC Pharmaceutical Group LTD is engaged in the manufacture and sale of pharmaceutical products. The group's segments include: Finished drugs, consisting research and development, manufacture and sale of pharmaceutical products and license fee income; Bulk products, that manufacture and sale of vitamin C, and antibiotic products in bulk powder form; and Functional food and others, that manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. It derives maximum revenue from Finished Products segments. Geographically, the company operates in Chinese Mainland, which Chinese Mainland generates maximum revenue; Other Asian regions; Europe; North America; and Others.
85GF Score

Get the complete analysis for FRA:CVGU

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.68
Price
€2.78
GF Value